Chronic Obstructive Pulmonary Disease (COPD) Clinical Trial
Official title:
EMG Measurements of Respiratory Muscles for the Titration of Nocturnal Non-invasive Ventilation in Stable Chronic Obstructive Pulmonary Disease Patients: A Randomized Controlled Trial
The aim of the present study is to investigate whether additional titration on surface electromyography (EMG) of the diaphragm and intercostal muscles improves the outcome of chronic non-invasive ventilation in patients with COPD and stable chronic hypercapnic respiratory failure in terms of better gas exchange after six weeks, lung function, patient comfort and compliance, and less patient ventilator asynchrony. Therefore, the investigators set up a randomized, two-armed crossover trial comparing regular titration with additional respiratory EMG titration of NIV.
Rationale:
Long-term application of nocturnal non-invasive ventilation (NIV) in stable hypercapnic
chronic obstructive pulmonary disease (COPD) patients has long been controversial as study
results were not unequivocal. However, in the past 7 years, with a change in ventilatory
strategy, clear benefits of chronic NIV have been shown in COPD patients with chronic
hypercapnic respiratory failure (CHRF), though only in stable disease. As a consequence,
this so called high-intensity NIV, which is the concept of using higher positive inspiratory
airway pressures (IPAP) levels than used in most of the older trials in addition to
controlled ventilation with higher backup breathing frequencies aiming for maximal arterial
carbon dioxide (PaCO2) reduction, has gained increasing attention.
However, it is unknown how high-intensity NIV works, and how to titrate the optimal IPAP and
optimal backup breathing frequency. Measuring respiratory muscle activity might be a way to
titrate NIV in COPD.
Objective:
The aim of the present study is to investigate whether additional titration on surface
electromyography (EMG) of the diaphragm and intercostal muscles improves outcomes of chronic
NIV in patients with COPD and stable CHRF in terms of better gas exchange after six weeks,
lung function, patient comfort and compliance and less patient-ventilator asynchrony (PVA).
Study design:
A randomized, two-armed, crossover trial comparing regular titration with additional
respiratory EMG titration of NIV in stable hypercapnic COPD.
One group will be initiated on NIV according to standard care protocol. For the other group,
additional EMG measures whilst on NIV will be made to titrate NIV.
Protocol Regular NIV-set up (both groups) Subjects are initiated on NIV according to our own
local treatment protocol. NIV is initiated by a registered nurse of our home mechanical
ventilation (HMV) centre. Effectiveness is measured with transcutaneous measurements of
carbon dioxide (PtCO2).
NIV is supplied through a pressure cycled ventilator, applying both inspiratory airway
pressure and expiratory airway pressure to the patient (BiPAP; Synchrony, Respironics,
incorporated., Murrysville, USA). A nasal or full face mask (Mirage mask, ResMed Ltd, UK) of
proper size is used. The ventilator is set in a spontaneous/ time mode (S/T), with a backup
frequency. If needed O2 was added to obtain a saturation of ≥ 90%. A humidifier (HC 150
Fisher & Paykel Healthcare, Australia) is used if needed. In general, the nurse aims to
reach a setting with high inspiratory pressures and a moderate breathing backup frequency,
with good patient comfort.
Start of the study Patients will be included in the study once they is used to the mask, can
sleep at least 6 hours with the ventilator and settings are set as is usual in daily
clinical practice. This means that the initial NIV settings are optimized according to the
results of an overnight PtCO2 and patient comfort. In daily practice, the specialized nurses
of the HMV centre already aim to increase the inspiratory pressure to the highest pressure
that is still comfortable for the patient, so that all patients will already be at their
highest tolerable pressure.
Once patients agree to participate, a 15-minute EMG measurement is done in all patients
while they are ventilated with the settings at that particular moment. Furthermore, patients
are asked to complete the severe respiratory insufficiency (SRI) questionnaire.
In the "nurse titrated NIV" group, no additional changes are made to the ventilatory
settings. In the "EMG titrated NIV" group, after a 15-minute EMG with the ventilatory
settings set by the nurse, the nurse will decrease the backup breathing frequency set by the
ventilator by steps of 2 breaths/min to 8 breaths/min (to achieve a pressure support mode of
ventilation (completely triggered by the patient)) and then again up to a frequency 2
breaths/min above their spontaneous breathing frequency while on the ventilator (to achieve
a controlled mode of ventilation). Each frequency will be measured for 10 minutes, so that
the total titration will take about 60-80 minutes. EMG measurements will be done throughout
the whole session and will be analyzed the same day. Then, the setting is chosen with the
lowest EMG activity and least PVA. The next night an EMG measurement is performed at the
chosen setting.
6 weeks After 6 weeks, the overnight EMG measurement is repeated in all patients.
Furthermore, a nocturnal PtCO2 measurement is performed, patients are asked to rate how
comfortable the patient is with the settings and are asked to fill in the SRI, lung function
is assessed and the number of hours use per night is read from the ventilator counting
reading. After these measurements are performed, patients are directed to the other
titration arm. In patients initially titrated by the nurse, an EMG frequency titration is
performed as described above. In the patients initially titrated additionally on the EMG,
the investigators will reset the ventilator to the settings applied by the nurse initially.
12 weeks After 12 weeks, the nocturnal EMG measurement, the nocturnal transcutaneous CO2
measurement, the comfort score, the SRI, lung function assessment and compliance rating are
repeated in all patients.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03282019 -
Study of Long-term HFNC for COPD Patients With HOT
|
N/A | |
Completed |
NCT05573464 -
A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
|
Phase 3 | |
Recruiting |
NCT06040086 -
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
|
Phase 3 | |
Not yet recruiting |
NCT06376994 -
Multi-Center Clean Air Randomized Controlled Trial in COPD
|
Phase 3 | |
Completed |
NCT02926534 -
Cross-Sectional Study of COPD Prevalence Among Smokers, Ex-smokers and Never-Smokers in Almaty, Kazakhstan
|
N/A | |
Completed |
NCT02728674 -
Management of Patients With Respiratory Symptoms in Sweden
|
N/A | |
Completed |
NCT02797392 -
Feasibility of a Preventive Program Against Lifestyle Related Diseases
|
N/A | |
Recruiting |
NCT02415478 -
Bronchioscopic Lung Volume Reduction (BLVR)
|
N/A | |
Completed |
NCT02512510 -
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT02774226 -
Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02459080 -
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT02518139 -
A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT03487406 -
Anti-platelet Therapy in the Prevention of Cardiovascular Disease in Patients With COPD (APPLE-COPD: ICON 2)
|
Phase 2 | |
Completed |
NCT01908140 -
Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT01893476 -
A Pragmatic Cluster Trial of a Tailored Intervention to Improve COPD Management
|
N/A | |
Withdrawn |
NCT01908933 -
Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema
|
Phase 3 | |
Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
Completed |
NCT01701869 -
Microbiology & Immunology of the Chronically-inflamed Airway
|
N/A | |
Recruiting |
NCT02527486 -
Seoul National University Airway Registry
|
N/A | |
Withdrawn |
NCT01377428 -
Efficacy of Indacaterol 150 µg Versus Formoterol
|
Phase 4 |